Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
2021 · JAMA Neurology · 566 citations
https://doi.org/10.1001/jamaneurol.2021.3671
M
Marta Milà‐Alomà
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
171
Papers
3.0K
Citations
22
h-index
39
i10-index
Marta Milà‐Alomà is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Dementia and Cognitive Impairment Research & Alzheimer's disease research and treatments & Functional Brain Connectivity Studies. The author has an h-index of 22, co-authored 146 publications.
ORCID: 0000-0002-5687-4597Papers by this author
worksNovel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s <i>continuum</i> when only subtle changes in Aβ pathology are detected
2020 · EMBO Molecular Medicine · 399 citations
https://doi.org/10.15252/emmm.202012921
Plasma and CSF biomarkers in a memory clinic: Head‐to‐head comparison of phosphorylated tau immunoassays
2022 · Alzheimer s & Dementia · 209 citations
https://doi.org/10.1002/alz.12841
Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer’s continuum
2021 · Alzheimer s Research & Therapy · 65 citations
https://doi.org/10.1186/s13195-021-00878-5
P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease
2021 · EMBO Molecular Medicine · 54 citations
https://doi.org/10.15252/emmm.202115098
Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer’s disease
2021 · Alzheimer s Research & Therapy · 24 citations
https://doi.org/10.1186/s13195-021-00781-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat